-
Mashup Score: 34Patient advocates, funding from Pharma, and how MRD negativity is about forcing payment not approval - 14 day(s) ago
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 450+ Peer Reviewed papers,…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37Targeting GPRC5D in multiple myeloma - 15 day(s) ago
The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies, ha…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 69In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease - 15 day(s) ago
Blood Cancer Journal – In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 10
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value enter ed is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. This value is admissible, but you may wish to double check it. This field must be a 5 or 9 digit U.S. ZIP Code (like 94043). Please re-enter it now. This field must be a 10 digit U.S. phone number (like 415 555 1212). Please re-enter it now. This
Source: redcap.iths.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 18
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and remains a major therapeutic challenge. There is substantial variability across transplantation and cellular therapy programs in assessing and managing post CAR-T failures in RRMM. The American Society for Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines conducted an online cross-sectional survey between September 2023 and December 2023 to determine the myeloma, transplantation and cellular therapy physicians’ practice patterns for surveillance, diagnosis, and management of CAR-T failure.
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Targeting Multiple Myeloma With the Latest Therapies - 18 day(s) ago
In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 49FDA Approves Cilta-Cel for R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy - 18 day(s) ago
The FDA has approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 79VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study - 19 day(s) ago
Blood Cancer Journal – VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
If you're someone with cancer, thinking about joining a patient advocacy group, watch this video. This is what they're not telling you about the funding. #mmsm https://t.co/eBL0lkJ3DB